Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial

Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist currently under US Food and Drug Administration (FDA) review for the acute treatment of migraine attacks. This double‐blind, four‐period crossover study compared the cardiac repolarization effect of therapeutic (100 mg)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacol Ther
Autori principali: Jakate, Abhijeet, Boinpally, Ramesh, Butler, Matthew, Lu, Kaifeng, McGeeney, Danielle, Periclou, Antonia
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7158215/
https://ncbi.nlm.nih.gov/pubmed/31628854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1696
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi